Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2018

Aug 09, 2018

SELL
$60.96 - $101.18 $318,089 - $527,957
-5,218 Closed
0 $0
Q1 2018

May 08, 2018

BUY
$73.28 - $102.95 $382,375 - $537,193
5,218 New
5,218 $478,000

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.4B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Stevens Capital Management LP Portfolio

Follow Stevens Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stevens Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Stevens Capital Management LP with notifications on news.